Ardent Health (ARDT) Projected to Release Earnings on Wednesday

Ardent Health (NYSE:ARDT) is expected to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.2320 per share and revenue of $1.60 billion for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 10:00 AM ET.

Ardent Health (NYSE:ARDT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.06). Ardent Health had a return on equity of 10.35% and a net margin of 1.22%. The business had revenue of $1.62 billion for the quarter, compared to analysts’ expectations of $1.59 billion. On average, analysts expect Ardent Health to post $0.96 EPS for the current fiscal year and $1.20 EPS for the next fiscal year.

Ardent Health Stock Down 0.6%

Shares of NYSE ARDT traded down $0.07 during midday trading on Tuesday, hitting $11.65. The company’s stock had a trading volume of 65,035 shares, compared to its average volume of 450,735. The business’s fifty day simple moving average is $11.18 and its two-hundred day simple moving average is $9.98. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.10 and a quick ratio of 1.99. Ardent Health has a 1 year low of $7.71 and a 1 year high of $14.99. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of 21.19, a price-to-earnings-growth ratio of 3.38 and a beta of 0.72.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ARDT. Royal Bank Of Canada increased their target price on shares of Ardent Health from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Monday, August 10th. Guggenheim boosted their price target on shares of Ardent Health from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen lowered Ardent Health from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Leerink Partners reiterated an “outperform” rating and issued a $14.00 price objective on shares of Ardent Health in a research note on Friday, September 18th. Finally, Zacks Research upgraded Ardent Health from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Seven analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $12.79.

Ardent Health Company Profile

Ardent Health is a U.S. healthcare services company that operates hospitals, outpatient facilities and physician practices. Its services include emergency and acute care, surgery, cardiology, orthopedics, oncology, women’s health, behavioral health, rehabilitation, imaging and other specialty and primary care offerings.

The company serves patients through regional health networks and hospital campuses primarily in Texas, Oklahoma, New Mexico and other U.S. markets. In addition to hospital-based care, Ardent operates outpatient clinics, urgent care locations and other facilities designed to provide services across different stages of the patient-care process.

Ardent Health was founded in 2001 and became a publicly traded company on the New York Stock Exchange in 2024.